VBIO — Valion Bio, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1787740 ·
Last close
$0.54
Market Cap
$482.3K
52W High
$67.50
52W Low
$0.47
ADV30
1,215,016
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -6,424,000 -7,103,000 32,473,000 2,108,000 28,227,000
Mar 2026 0 — -5,634,000 -6,202,000 38,215,000 7,215,000 27,153,000
Dec 2025 -302,000 — -1,975,000 -2,849,000 31,607,000 12,645,000 14,810,000
Sep 2025 146,000 -145,000 -2,483,000 -2,596,000 6,229,000 3,450,000 638,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-14,155,000
Investing CF
$-223,000
Financing CF
$16,090,000
CapEx
$-99,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-214.00
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-66,506,000
Inventory
$750,000
Receivables
$19,000
ST Investments
—
EBIT TTM
$-16,350,000
Pretax Income TTM
$-17,842,000
Interest Exp TTM
$1,339,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$-86,000
EBITDA
$-16,536,000
Free Cash Flow
$-8,062,250
Enterprise Value
$17,306,954
Total Cash
$2,108,000
Total Debt
$17,409,000
Shares Out
887,589
Trailing EPS
$-184.45
Book Value
$1.02
ROE
-459.5%
ROA
-57.1%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -7,898,000 -8,878,000 31,607,000 14,810,000 16,797,000 -6,999,000
Dec 2024 0 -4,476,000 -5,655,000 2,810,000 272,000 2,535,000 -5,725,000
Dec 2023 1,176,000 -8,245,000 -8,244,000 5,160,000 1,577,000 3,580,000 -8,511,000
Dec 2022 1,840,000 -10,098,000 -10,096,000 5,880,000 2,245,000 3,630,000 -8,919,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$-98,000
NetIncome TTM
$-18,750,000
OpCashFlow TTM
—
Assets (Latest)
$32,473,000
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
LABT Lakewood-Amedex Biotherapeutics Inc. $508.3K $0.21 —
EVFM Evofem Biosciences, Inc. $569.9K $0.00 —
CYTOF Altamira Therapeutics Ltd. $405.8K $0.07 —
BIOM BIOMOLECULAR LIFE HOLDINGS, INC. $580.8K $0.50 —
PTIX Protagenic Therapeutics, Inc.\new $814.6K $0.45 —

News headlines (Yahoo Finance, 1h cache)

Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
2026-11-17 13:05 · Yahoo
Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference
2026-11-11 13:10 · Yahoo
Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
2026-10-30 12:50 · Yahoo
Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation
2026-10-28 11:45 · Yahoo
Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options
2026-10-26 12:00 · Yahoo
Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value
2026-10-21 12:00 · Yahoo
Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone
2026-10-15 12:00 · Yahoo
With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge
2026-10-14 12:15 · Yahoo
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand
2026-10-09 11:45 · Yahoo
Valion Bio Completes Oral Mucosal Entolimod Formulation, Opening Potential Needle-Free Development Pathway
2026-09-30 14:41 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.